GILEAD SCIENCES INC

NASDAQ: GILD (Gilead Sciences, Inc.)

Last update: 15 Apr, 11:53PM

105.68

-0.82 (-0.77%)

  • 1D -0.77%
  • 5D 1.09%
  • 1M -5.03%
  • 6M 18.07%
  • YTD 15.02%
  • 1Y 61.32%
  • 5Y 32.18%
Previous Close 106.50
Open 106.40
Volume 7,491,986
Avg. Volume (3M) 9,359,521
Market Cap 131,743,858,688
Price / Earnings (TTM) 278.11
Price / Earnings (Forward) 13.11
Price / Sales 4.52
Price / Book 6.73
52 Weeks Range
62.07 (-41%) — 119.96 (13%)
Earnings Date 24 Apr 2025
TTM Dividend Yield 2.93%
Profit Margin 20.76%
Operating Margin (TTM) 38.49%
Diluted EPS (TTM) 4.76
Quarterly Revenue Growth (YOY) -0.30%
Quarterly Earnings Growth (YOY) 24.80%
Total Debt/Equity (MRQ) 131.10%
Current Ratio (MRQ) 1.30
Operating Cash Flow (TTM) 10.37 B
Levered Free Cash Flow (TTM) 12.71 B
Return on Assets (TTM) 12.00%
Return on Equity (TTM) 32.65%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bearish Bullish
Drug Manufacturers - General (Global) Bearish Bullish
Stock Gilead Sciences, Inc. Bullish Bullish

AIStockmoo Score

-0.2
Analyst Consensus 1.5
Insider Activity -1.5
Price Volatility -0.5
Technical Moving Averages 0.0
Technical Oscillators -0.5
Average -0.20

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
GILD 132 B 2.93% 278.11 6.73
AMGN 152 B 3.23% 37.39 25.88
AZN 230 B 2.26% 30.43 6.19
SNY 127 B 8.05% 20.32 1.52
GRFS 6 B - 28.00 0.740
BIIB 17 B - 10.56 1.05

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Value
% Held by Insiders 0.12%
% Held by Institutions 89.62%
52 Weeks Range
62.07 (-41%) — 119.96 (13%)
Price Target Range
90.00 (-14%) — 140.00 (32%)
High 140.00 (Wells Fargo, 32.48%) Buy
Median 125.00 (18.28%)
Low 90.00 (RBC Capital, -14.84%) Hold
Average 119.27 (12.86%)
Total 9 Buy, 2 Hold
Avg. Price @ Call 106.58
Firm Date Target Price Call Price @ Call
Morgan Stanley 25 Apr 2025 135.00 (27.74%) Buy 103.17
11 Mar 2025 130.00 (23.01%) Buy 114.43
Oppenheimer 25 Apr 2025 125.00 (18.28%) Buy 103.17
04 Mar 2025 132.00 (24.91%) Buy 114.74
Cantor Fitzgerald 22 Apr 2025 125.00 (18.28%) Buy 105.51
JP Morgan 27 Mar 2025 130.00 (23.01%) Buy 111.16
B of A Securities 05 Mar 2025 126.00 (19.23%) Buy 115.44
Wells Fargo 05 Mar 2025 140.00 (32.48%) Buy 115.44
12 Feb 2025 120.00 (13.55%) Buy 103.31
Deutsche Bank 18 Feb 2025 120.00 (13.55%) Buy 105.25
BMO Capital 12 Feb 2025 115.00 (8.82%) Buy 103.31
Goldman Sachs 12 Feb 2025 96.00 (-9.16%) Hold 103.31
Piper Sandler 12 Feb 2025 110.00 (4.09%) Buy 103.31
RBC Capital 12 Feb 2025 90.00 (-14.84%) Hold 103.31
03 Feb 2025 84.00 (-20.51%) Hold 98.38
Show more

No data within this time range.

  • 3M
Date Type Details
29 Apr 2025 Announcement Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
29 Apr 2025 Announcement Gilead Sciences to Present at Upcoming Investor Conferences
28 Apr 2025 Announcement Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development
24 Apr 2025 Announcement Gilead Sciences Announces First Quarter 2025 Financial Results
24 Apr 2025 CNBC Corporate America shelled out millions for Trump's inauguration. Now he's upending many of their businesses
21 Apr 2025 Announcement Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer
10 Apr 2025 Announcement Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025
12 Mar 2025 Announcement Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
11 Mar 2025 Announcement First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
24 Feb 2025 Announcement European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention
20 Feb 2025 Announcement Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
19 Feb 2025 Announcement Gilead Sciences to Present at Upcoming Investor Conferences
18 Feb 2025 Announcement U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
13 Feb 2025 CNBC U.S. investors, Big Pharma race to find new medicines in China
11 Feb 2025 Announcement Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 Dividend
11 Feb 2025 Announcement Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results
Show more
TTM Dividend Yield 2.93%
5Y Average Dividend Yield 3.80%
Payout Ratio 65.13%
Expected Next Dividend Payment Jun 2025
Ex Date Announcement Date Payment Date Details
14 Mar 2025 05 Feb 2025 28 Mar 2025 0.79 Cash
13 Dec 2024 30 Oct 2024 30 Dec 2024 0.77 Cash
13 Sep 2024 30 Jul 2024 27 Sep 2024 0.77 Cash
14 Jun 2024 23 Apr 2024 27 Jun 2024 0.77 Cash
14 Mar 2024 01 Feb 2024 28 Mar 2024 0.77 Cash
14 Dec 2023 01 Nov 2023 28 Dec 2023 0.75 Cash
14 Sep 2023 25 Jul 2023 28 Sep 2023 0.75 Cash
14 Jun 2023 25 Apr 2023 29 Jun 2023 0.75 Cash
14 Mar 2023 25 Jan 2023 30 Mar 2023 0.75 Cash
14 Dec 2022 25 Oct 2022 29 Dec 2022 0.73 Cash
14 Sep 2022 25 Jul 2022 29 Sep 2022 0.73 Cash
14 Jun 2022 27 Apr 2022 29 Jun 2022 0.73 Cash
14 Mar 2022 28 Jan 2022 30 Mar 2022 0.73 Cash
14 Dec 2021 26 Oct 2021 30 Dec 2021 0.71 Cash
14 Sep 2021 26 Jul 2021 29 Sep 2021 0.71 Cash
14 Jun 2021 27 Apr 2021 29 Jun 2021 0.71 Cash
12 Mar 2021 02 Feb 2021 30 Mar 2021 0.71 Cash
14 Dec 2020 26 Oct 2020 30 Dec 2020 0.68 Cash
14 Sep 2020 29 Jul 2020 29 Sep 2020 0.68 Cash
11 Jun 2020 29 Apr 2020 29 Jun 2020 0.68 Cash
12 Mar 2020 03 Feb 2020 30 Mar 2020 0.68 Cash
12 Dec 2019 23 Oct 2019 30 Dec 2019 0.63 Cash
12 Sep 2019 29 Jul 2019 27 Sep 2019 0.63 Cash
13 Jun 2019 01 May 2019 27 Jun 2019 0.63 Cash
14 Mar 2019 01 Feb 2019 28 Mar 2019 0.63 Cash
13 Dec 2018 24 Oct 2018 28 Dec 2018 0.57 Cash
13 Sep 2018 24 Jul 2018 27 Sep 2018 0.57 Cash
14 Jun 2018 30 Apr 2018 28 Jun 2018 0.57 Cash
15 Mar 2018 05 Feb 2018 29 Mar 2018 0.57 Cash
14 Dec 2017 25 Oct 2017 28 Dec 2017 0.52 Cash
14 Sep 2017 25 Jul 2017 28 Sep 2017 0.52 Cash
14 Jun 2017 01 May 2017 29 Jun 2017 0.52 Cash
14 Mar 2017 06 Feb 2017 30 Mar 2017 0.52 Cash
13 Dec 2016 31 Oct 2016 29 Dec 2016 0.47 Cash
14 Sep 2016 22 Jul 2016 29 Sep 2016 0.47 Cash
14 Jun 2016 27 Apr 2016 29 Jun 2016 0.47 Cash
14 Mar 2016 02 Feb 2016 30 Mar 2016 0.43 Cash
14 Dec 2015 26 Oct 2015 30 Dec 2015 0.43 Cash
14 Sep 2015 23 Jul 2015 29 Sep 2015 0.43 Cash
12 Jun 2015 24 Apr 2015 29 Jun 2015 0.43 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 0.790 1 0.75
2024 3.08 4 3.33
2023 3.00 4 3.70
2022 2.92 4 3.40
2021 2.84 4 3.91
2020 2.72 4 4.67
2019 2.52 4 3.88
2018 2.28 4 3.65
2017 2.08 4 2.90
2016 1.84 4 2.57
2015 1.29 3 1.28
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria